About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

Astellas Pharma Inc.(4503) Summary

4503
TSE Prime
Astellas Pharma Inc.
1,333.5
JPY
+76.5
(+6.09%)
Apr 10, 3:30 pm JST
9.08
USD
Apr 10, 2:30 am EDT
Result
PTS
outside of trading hours
1,323
Apr 10, 6:35 pm JST
Summary Chart Historical News Financial Result
PER
170.5
PBR
1.60
Yield
5.55%
Margin Trading Ratio
30.74
Stock Price
Apr 10, 2025
Opening Apr 10, 9:09 am
1,350.0 JPY 9.16 USD
Previous Close Apr 9
1,257.0 JPY 8.64 USD
High Apr 10, 9:17 am
1,361.0 JPY 9.24 USD
Low Apr 10, 2:17 pm
1,320.5 JPY 9.00 USD
Volume
10,732,500
Trading Value
0.01T JPY 0.10B USD
VWAP
1335.34 JPY 9.1 USD
Minimum Trading Value
133,350 JPY 908 USD
Market Cap
2.41T JPY 0.02T USD
Number of Trades
11,881
Liquidity & Number of Trades
As of Apr 10, 2025
Liquidity
High
1-Year Average
6,050
1-Year High Aug 6, 2024
25,178
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 4, 2025 153,800 3,937,000 25.60
Mar 28, 2025 154,100 3,809,200 24.72
Mar 21, 2025 148,700 3,851,200 25.90
Mar 14, 2025 158,900 4,030,800 25.37
Mar 7, 2025 163,800 4,025,700 24.58
Company Profile
Astellas Pharma Inc. is the second-largest pharmaceutical company in Japan, specializing in innovative drugs. The company has particular strengths in urology and transplantation, and is focusing on anticancer drugs.
Sector
Pharmaceuticals
Astellas Pharma Inc. was formed in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical. The company's main business is the research and development, manufacturing, and sales of pharmaceuticals, with operations spanning globally. In research and development, Astellas focuses on cutting-edge fields such as regenerative medicine and gene therapy, primarily through its U.S. subsidiaries. The company has 11 production sites worldwide, including in Ireland, the Netherlands, and China. Its sales network covers approximately 70 countries where it conducts direct sales, including the United States, Germany, China, France, Spain, and South Korea. Astellas has established an integrated pharmaceutical business across its group, collaborating with regional affiliates to supply raw materials and products. The company operates in a single business segment - pharmaceuticals - leveraging its global R&D infrastructure and sales network for business expansion.